Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States.
The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures.
Its product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies.
The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022.
Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
| Country | United States |
| Founded | 1986 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 406 |
| CEO | Paul Josephs |
Contact Details
Address: 3515 Lyman Boulevard Chaska, Minnesota 55318 United States | |
| Phone | 952 368 4300 |
| Website | lifecore.com |
Stock Details
| Ticker Symbol | LFCR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0001005286 |
| ISIN Number | US5147661046 |
| Employer ID | 94-3025618 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Josephs | President, Chief Executive Officer and Director |
| Ryan D. Lake CPA | Executive Vice President and Chief Financial Officer |
| Aaron Perlitsh | Director of Internal Audit and Chief Compliance Officer |
| Jackie Q. Klecker | Executive Vice President of Quality and Development Services |
| Mark DaFonseca | Chief Commercial Officer |
| Parker K. Javid | Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 26, 2025 | 8-K | Current Report |
| Sep 23, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 18, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 18, 2025 | 8-K | Current Report |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 7, 2025 | 10-K | Annual Report |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 18, 2025 | 8-K | Current Report |
| Jul 17, 2025 | SCHEDULE 13G | Filing |